Barely Significant

Excerpts

8,476 sentences · 1 filter applied

In contrast, in the aged group, M1 number showed an increasing trend during the observation period ( p values for main effects of post-surgery time and mouse age and their interaction: 0.0046, 0.0299, and 0.0020, respectively; two-way factorial ANOVA), resulting in significantly higher M1 number on day 7 ( p value: 0.0047; Tukey’s post-hoc test) ( Figure 2 a and Supplementary Table S1 ).
Interestingly, the suppressive effects on the gene expression of inflammatory cytokines and Nf-κb and the enhancing effects on the M2-related genes in M1 showed significant ( Il-6 , iNos , Ym-1 , Fizz-1 ) or marginally significant ( Tnf-α , Nf-κb ) reduction when supernatants from aged MSCs were used (mean relative expression levels in M1 with young vs. aged MSCs and p values: Il-6 [1.01 vs. 2.16, 0.0091], iNos [0.50 vs. 1.11, 0.0308], Tnf-α [0.57 vs. 0.76, 0.0466], Nf-κb [0.15 vs. 0.65, 0.0409], Arg-1 [2.67 vs. 2.39, 0.1322], Ym-1 [3.46 vs. 2.26, 0.0014], and Fizz-1 [4.81 vs. 2.62, 0.0093]; Tukey’s post-hoc test) ( Figure 5 d–f and Supplementary Table S2 ). 2.6.
In a separate analysis of genes that were down- and upregulated, the KEGG MAPK signaling pathway (GO:0000165) ( DUSP1 , FOS , GADD45A ) and endocytosis (GO:0006897) ( PARD6B , KIF5C , MHCX1 ) showed a trend toward enrichment (FDR = 0.06) with downregulated genes, while fatty acid degradation (GO:0009062) and pyruvate metabolism (GO: 0006090) ( LOC100034175 ) were enriched (FDR < 0.05) with upregulated genes.
highly significantqualifiedgold
A prospective, randomized, double-blinded phase I clinical trial recruiting 38 patients with severe diffuse coronary artery disease refractory to medication and unsuitable for coronary intervention, who were subjected to intra-coronary CD34+ cell infusion after subcutaneous granulocyte colony-stimulating factor (G-CSF) administration twice a day for four days, showed highly significant improvements in left ventricular ejection fraction and increases in neovascularization, as well as the alleviation of angina and heart failure symptoms [ 49 ].
Stem Cell Therapy against Ischemic Heart Disease.
Int J Mol Sci · 2024 · PMC11011361